Efficacy of talc pleurodesis in patients with malignant pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion? Source: International Congress 2017 – Pleural and mediastinal malignancies Year: 2017
Predictors of successful pleurodesis for patients with malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 493s Year: 2004
Efficacy and safety of talc pleurodesis in patients with malignant pleural effusions Source: Eur Respir J 2006; 28: Suppl. 50, 754s Year: 2006
Comparison in effectiveness and proinflammatory mediators between talc, doxycycline and tetracycline for pleurodesis in malignant pleural effusions (MPE) Source: Annual Congress 2006 - New developments in diagnostic and therapeutic bronchoscopy and thoracoscopy Year: 2006
Systemic treatment of malignant pleural effusion Source: Annual Congress 2005 - What's new in the pleura Year: 2005
Polarized cytokine profiles in the peripheral blood and pleural fluid from the patients with tuberculous pleurisy, pulmonary tuberculosis combined disease, and malignant pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 467s Year: 2004
Pleurodesis in the treatment of malignant pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 628s Year: 2004
Videothoracoscopy in the treatment of malignant pleural effusions Source: Annual Congress 2009 - Pleural and mediastinal diseases Year: 2009
Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007
Malignant pleural effusions Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=177 Year: 2002
The profile of neutrophils and D-dimer in pleural fluid is useful to monitor the pleurodesis process after talc poudrage in malignant pleural effusions (MPE) Source: Eur Respir J 2002; 20: Suppl. 38, 70s Year: 2002
Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients Source: Eur Respir J 2011; 38: 1425-1430 Year: 2011
Thoracoscopic evaluation of the effect of tumour burden on the outcome of pleurodesis in malignant pleural effusion Source: Virtual Congress 2021 – Pleural disease and bronchoscopic lung volume reduction Year: 2021
The value of biochemical parameters of the pleural aspirate in predicting success of chemical pleurodesis in malignant pleural effusion Source: Annual Congress 2010 - Oncological problems, surgical risk and complications Year: 2010
Pleurodesis with erythromycin in large and recurrent malignant pleural effusions Source: Eur Respir J 2005; 26: Suppl. 49, 72s Year: 2005
Predictors of survival in patients with recurrent malignant pleural effusion Source: Annual Congress 2008 - Diagnostic and therapeutic approaches in pleural diseases Year: 2008
Prognostic significance of pleural tumour burden in patients with malignant pleural effusions Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
Evaluation of concomitant pleural effusions in patients with lung cancers Source: Eur Respir J 2007; 30: Suppl. 51, 668s Year: 2007
Is it important to determine pleural fluid amylase in patients with malignant pleural effusions? Source: Eur Respir J 2007; 30: Suppl. 51, 565s Year: 2007